Durect (Durect) 14-Day RSI

: 40.40 (As of Today)

View and export this data going back to 2000. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-23), Durect's 14-Day RSI is 40.40.

The industry rank for Durect's 14-Day RSI or its related term are showing as below:

DRRX's 14-Day RSI is ranked better than
67.81% of 1140 companies
in the Drug Manufacturers industry
Industry Median: 45.21 vs DRRX: 40.40

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Durect 14-Day RSI Distribution

For the Drug Manufacturers industry and Healthcare sector, Durect's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Durect's 14-Day RSI falls into.

Durect (NAS:DRRX) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI

100

–

[ 100

( 1 + Average Gain

Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Durect (NAS:DRRX) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Durect 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Durect's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.

Durect (Durect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » 14-Day RSI

Comparable Companies

Traded in Other Exchanges

DC8A:Germany

Address

10260 Bubb Road, Cupertino, CA, USA, 95014

Website

https://www.durect.com

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Executives

Judith J. Robertson	director	10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis	director	364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp	officer: Chief Financial Officer	C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia	director	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman	officer: Chief Medical Officer	C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice	officer: Sr. VP Operations & Corp QA	10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp	10 percent owner	1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe	director	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg	officer: Chief Financial Officer	10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown	director, officer: President & CEO	10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105